Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIVEC: Neo-adjuvant T-VEC + Nivolumab in Melanoma
NCT04330430Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2020
- Primary completion
- Apr 2023
- Modality
- Oncolytic Viruses, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec and nivolumab in melanoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Pathologic response at 12 weeks. Started Sep 2020; status: completed.
02
Drugs
talimogene laherparepvecnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04330430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04330430.